ergoloid mesylates- dihydroergocornine mesylate, dihydroergocristine mesylate, dihydro-.alpha.-ergocryptine mesylate, and dihydr
sun pharmaceutical industries, inc. - dihydroergocornine mesylate (unii: 42rx8kpw29) (dihydroergocornine - unii:ik4c1oc8ne), dihydroergocristine mesylate (unii: ds7cl18uam) (dihydroergocristine - unii:05d48lum4z), dihydro-.alpha.-ergocryptine mesylate (unii: z4i7bu58dn) (dihydro-.alpha.-ergocryptine - unii:202229ir8y), dihydro-.beta.-ergocryptine mesylate (unii: 79y4u49i29) (epicriptine - unii:5m64643b5u) - dihydroergocornine mesylate 0.333 mg - a proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. the identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. it appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, alzheimer's dementia, senile onset, multi-infarct dementia). before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. particular care should be taken to exclude delirium and dementiform illness secon
ergoloid mesylates- dihydroergocornine mesylate, dihydroergocristine mesylate, dihydro-.alpha.-ergocryptine mesylate, and dihydr
carilion materials management - dihydroergocornine mesylate (unii: 42rx8kpw29) (dihydroergocornine - unii:ik4c1oc8ne), dihydroergocristine mesylate (unii: ds7cl18uam) (dihydroergocristine - unii:05d48lum4z), dihydro-.alpha.-ergocryptine mesylate (unii: z4i7bu58dn) (dihydro-.alpha.-ergocryptine - unii:202229ir8y), dihydro-.beta.-ergocryptine mesylate (unii: 79y4u49i29) (epicriptine - unii:5m64643b5u) - dihydroergocornine mesylate 0.333 mg - a proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. the identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. it appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, alzheimer's dementia, senile onset, multi-infarct dementia). before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. particular care should be taken to exclude delirium and dementiform illness secon
hydergine tablets, 1mg
sterimax inc - ergoloid mesylates - tablet - 1mg - ergoloid mesylates 1mg - sympatholytic (adrenergic blocking) agents
ergoloid mesylates tablets usp oral 1mg
frontida biopharm, inc. - dihydroergocornine mesylate (unii: 42rx8kpw29) (dihydroergocornine - unii:ik4c1oc8ne), dihydroergocristine mesylate (unii: ds7cl18uam) (dihydroergocristine - unii:05d48lum4z), dihydro-.alpha.-ergocryptine mesylate (unii: z4i7bu58dn) (dihydro-.alpha.-ergocryptine - unii:202229ir8y), dihydro-.beta.-ergocryptine mesylate (unii: 79y4u49i29) (epicriptine - unii:5m64643b5u) -
hydergine tablets 1.5 mg
novartis - ergoloid mesilates - tablet - 1.5 mg
medoflucon 150mg capsules
medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - fluconazole - hard capsule - fluconazole 150 mg - antimycotics for systemic use
noradrenaline (norepinephrine) 1 mg/ml concentrate for solution for infusion
as kalceks - noradrenaline - concentrate for solution for infusion - 1 milligram(s)/millilitre - norepinephrine
noradrenaline concentrate for solution for infusion
kalceks jsc - noradrenaline (noradrenaline tartrate) - concentrate for solution for infusion - 1mg/ml
noradrenaline concentrate for solution for infusion
kalceks jsc - noradrenaline tartrate - concentrate for solution for infusion - 1mg/ml
noradrenaline (norepinephrine) kabi 1 mg/ml concentrate for solution for infusion
fresenius kabi deutschland gmbh - sodium chloride; noradrenaline tartrate - concentrate for solution for infusion - 1 milligram(s)/millilitre - norepinephrine